Project Grant R01DK144425
Award Date 9/1/25
Completion Date 8/31/29
Dollars Obligated $3.1M
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
- This federal Project Grant award of $208,428, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research), aims to enhance the safety and efficacy of stem cell-derived islet transplantation for treating type 1 diabetes. The key objectives are to improve the survival and engraftment of the transplanted cells, enable long-term insulin independence, and develop safety mechanisms to retrieve the graft...
- This $2,782,476 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847) supports research to determine the molecular mechanisms underlying pancreatic beta cell response to metabolic stress, a key factor in the development of type 2 diabetes. The 4-year project aims to leverage in vitro human beta cell models, single-cell transcriptomic analyses, and targeted drug screening to delineate the dynamic chromatin and transcriptomic changes that...
- This $146,829 Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to investigate the molecular mechanisms by which the bacterial protein BEFA (beta-cell expansion factor A) induces the proliferation and metabolic maturation of pancreatic beta cells. The research, conducted at the University of Oregon, utilizes single-cell imaging, genetic...
- This federal Project Grant award of $641,794 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant aims to elucidate the mechanisms that protect beta-cells from DNA damage during periods of growth and adaptation, in order to maintain beta-cell homeostasis and prevent the loss of functional beta-cells, a key factor in the development of type 1 and type 2...
- This $681,562 Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) aims to investigate approaches for enhancing the metabolic maturity and functionality of human pluripotent stem cell-derived islet organoids, with the goal of improving their survival and efficacy for transplantation as a treatment for type 1 diabetes. The research will examine the use of pharmacological agents...
- This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $199,258 to The Leland Stanford Junior University to conduct research aimed at advancing cell-based therapies for Type 1 Diabetes Mellitus (T1D). The key objectives are to: 1) establish effective, non-toxic strategies to induce immune tolerance toward donor tissues for islet cell...
- This federal Project Grant award of $2,390,830 from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847) aims to develop scalable and transplantable pancreatic islet organoids with engineered oxygenation. The 4-year project, awarded on September 1, 2025, will be carried out by the University of California, San Francisco. The research seeks to create an islet-supportive microenvironment to improve islet engraftment efficiency for Type 1 diabetes patients undergoing...
- The University of California, Davis received a $126,480 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847) to conduct research on the role of the signaling protein 14-3-3-z in regulating the crosstalk between pancreatic islet cells. The research aims to define a new pathway regulating 14-3-3-z expression in beta cells and investigate how this impacts alpha cell function and glucose-stimulated insulin secretion. This project is expected...
- This federal Project Grant award of $568,075.00 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award to Brigham Young University aims to determine the role of the transcription factor NR4A1 in the pathways that expand functional beta cell mass, which is critical for treating type 1 and type 2 diabetes. The research seeks to understand how NR4A1 is...
- This $372,067 Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports the development of an immune evasive stem cell line for type 1 diabetes regenerative therapy. The grant recipient, Aleutian Therapeutics, Inc., a biotechnology company in Los Angeles, California, is conducting research to create gene editing technologies that enable allogeneic...